Article
Vascular phenotypes in primary non-small cell lung carcinomas and matched brain metastases.
British journal of cancer - 7 Jun 2011
Jubb A M, Cesario A, Ferguson M, Congedo M T, Gatter K C, Lococo F, Mulè A, Pezzella F
Abstract excerpt
BACKGROUND: Anti-angiogenic therapy with bevacizumab (an anti-vascular endothelial growth factor (VEGF) antibody) predominantly targets immature blood vessels. Bevacizumab has shown a survival benefit in non-small cell lung carcinoma (NSCLC) and has recently been demonstrated to be safe in patients with brain metastases. However, it is not known whether bevacizumab is effective against brain metastases or whether...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
